Amphastar Pharmaceuticals (AMPH) & Its Rivals Head-To-Head Review
Amphastar Pharmaceuticals (NASDAQ: AMPH) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Amphastar Pharmaceuticals to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.
This is a summary of recent ratings for Amphastar Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Amphastar Pharmaceuticals Competitors||840||3775||6798||185||2.55|
Insider and Institutional Ownership
44.0% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Amphastar Pharmaceuticals has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals’ rivals have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
This table compares Amphastar Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Amphastar Pharmaceuticals Competitors||-2,859.74%||-67.95%||-9.23%|
Valuation and Earnings
This table compares Amphastar Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Amphastar Pharmaceuticals||$249.62 million||$17.41 million||226.90|
|Amphastar Pharmaceuticals Competitors||$8.20 billion||$2.68 billion||-1.59|
Amphastar Pharmaceuticals’ rivals have higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Amphastar Pharmaceuticals beats its rivals on 7 of the 13 factors compared.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.